Platinum-based combination therapy is usually recommended as initial therapy for advanced NSCLC that does not involve targeted mutations, regardless of programmed death ligand 1 (PD-L1) status (1, 2). This evidence concerns the gene CD274 and non-small cell lung carcinoma.